BiotechTube

ranibizumab 0.5mg

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Choroidal Neovascularisation

Conditions

Choroidal Neovascularisation

Trial Timeline

Jan 1, 2010 → May 1, 2012

NCT ID
NCT01037348

About ranibizumab 0.5mg

ranibizumab 0.5mg is a phase 2 stage product being developed by Novartis for Choroidal Neovascularisation. The current trial status is completed. This product is registered under clinical trial identifier NCT01037348. Target conditions include Choroidal Neovascularisation.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT02032173Phase 3Terminated
NCT01037348Phase 2Completed

Competing Products

20 competing products in Choroidal Neovascularisation

See all competitors
ProductCompanyStageHype Score
Zimura + EyleaAstellas PharmaPhase 2
52
Avacincaptad PegolAstellas PharmaPhase 2
52
Verteporfin Photodynamic Therapy + RanibizumabNovartisApproved
85
ranibizumabNovartisApproved
85
RanibizumabNovartisApproved
85
Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDTNovartisPhase 3
77
ranibizumabNovartisPhase 3
77
Everolimus + RanibizumabNovartisPhase 2
52
RanibizumabNovartisPhase 3
77
ranibizumabNovartisPhase 3
77
Brolucizumab 6mg + Brolucizumab 6mgNovartisPhase 3
77
Intravitreal injection ranibizumabNovartisPhase 2
52
RanibizumabNovartisPhase 3
77
RanibizumabNovartisPhase 1/2
41
Faricimab + Ranibizumab + Sham ProcedureRochePhase 2
52
Faricimab + RanibizumabRochePhase 3
77
Faricimab + Ranibizumab + Sham ProcedureRochePhase 2
52
Intravitreal PegaptanibPfizerPre-clinical
22
Intravitreal aflibercept injection 2.0mgRegeneron PharmaceuticalsApproved
84
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)Regeneron PharmaceuticalsPre-clinical
22

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85